New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
11:37 EDTMDT, EWMedtronic says jury awarded Edwards Lifesciences damages of $392.5M
A jury in the Federal District Court of Delaware today decided in favor of Edwards Lifesciences (EW), ruling that the Medtronic (MDT) CoreValve System infringed on Edward's Cribier patent. Medtronic intends to appeal. "While we are disappointed in the jury's verdict, we continue to believe that this decision will be overturned on appeal," said Neil Ayotte, vice president and acting general counsel at Medtronic. "Medtronic has prevailed against Edwards in several legal actions related to a European counterpart to this patent and others, and believes the Federal Circuit Court of Appeals will find no merit to Edward's infringement claim. Today's jury verdict does not impose an injunction, and Medtronic will oppose any requests for an injunction by Edwards." The jury found willful infringement and awarded Edwards total damages in the amount of $392.5M. Medtronic anticipates U.S. regulatory approval of the CoreValve System for extreme risk patients by the end of its FY14, and intends to begin selling the device in the U.S. at that time.
News For MDT;EW From The Last 14 Days
Check below for free stories on MDT;EW the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 27, 2014
05:40 EDTMDTMedtronic sees impact of NGC Medical acquisition neutral to FY15 earnings
Subscribe for More Information
August 26, 2014
19:33 EDTMDTCovidien shareholder sues to block sale to Medtronic, Bloomberg reports
Subscribe for More Information
05:54 EDTMDTMedtronic acquires Sapiens SBS for $200M
Subscribe for More Information
August 25, 2014
10:03 EDTMDTMedtronic announces FDA approval of Viva CRT-P for heart failure or AV block
Subscribe for More Information
August 24, 2014
21:54 EDTEWPiper Jaffray to hold a bus tour
Subscribe for More Information
August 21, 2014
08:29 EDTEWEdwards Lifesciences price target raised to $120 from $97 at JMP Securities
Subscribe for More Information
August 20, 2014
08:47 EDTMDTMedtronic valuation attractive, says Morgan Stanley
Morgan Stanley said Medtronic's (MDT) valuation is attractive given pipeline execution, margin growth and shareholder returns, and expectations for the Covidien (COV) deal to go through. Shares are Overweight rated
07:18 EDTMDTMedtronic shares have upside with or without deal, says Deutsche Bank
Deutsche Bank sees limited downside risk and significant upside potential for shares of Medtronic (MDT), with or without the pending Covidien (COV) acquisition. Deutsche says the Q1 results show improving trends and it keeps a Buy rating on Medtronic with an $85 price target.
August 19, 2014
08:40 EDTMDTMedtronic sees FY15 gross margin of 74.5%-75%, with Q2 on lower end of range
Subscribe for More Information
08:25 EDTMDTMedtronic: Negative factors in Spine segment in Q1 werre temporary
Subscribe for More Information
08:22 EDTMDTMedtronic: We will continue to pay significant US taxes following Covidien deal
Subscribe for More Information
07:19 EDTMDTMedtronic backs FY15 EPS view of $4.00-$4.10, consensus $4.04
Subscribe for More Information
07:17 EDTMDTMedtronic reports Q1 EPS 93c, consensus 92c
Reports Q1 revenue $4.27B, consensus $4.25B.
August 18, 2014
15:26 EDTMDTNotable companies reporting before tomorrow's open
Subscribe for More Information
14:49 EDTMDTMedtronic technical comments before earnings
Subscribe for More Information
13:59 EDTMDTMedtronic August weekly 63.5 straddle priced for 2% move into Q1
Subscribe for More Information
06:24 EDTMDTOptions expected to be active
Subscribe for More Information
August 14, 2014
07:27 EDTMDTJPMorgan a buyer of Medtronic at current levels
Subscribe for More Information
06:15 EDTMDTCovidien risk/reward very favorable, says Citigroup
Subscribe for More Information
August 13, 2014
08:25 EDTMDTMedtronic August weekly volatility elevated into Q1 and outlook
Medtronic August weekly call option implied volatility is at 24, September is at 19, November is at 18; compared to its 26-week average of 19 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on August 19.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use